Navigation Links
BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies
Date:3/9/2011

CARY, N.C., March 9, 2011 /PRNewswire/ -- iAdvantage Software, Inc., a leading solutions provider for managing development and pre-clinical life science studies, today announced that BioTox Sciences (BTS), a GLP Contract Research Organization, headquartered in San Diego, California, is deploying the eStudy™ hosted solution to manage its GLP and Non-GLP preclinical/nonclinical studies.

(Logo: http://photos.prnewswire.com/prnh/20110309/CL62195LOGO)

In 2010, BioTox Sciences expanded its resources from people to facility to accommodate growing Sponsors' needs.  The final challenge was selecting a software platform that would handle the different preclinical study types BTS conduct's today, yet flexible enough to meet the ever-changing needs they may encounter as they continue to grow.

"After weighing our options and careful due diligence, BioTox Sciences chose to implement eStudy, by iAdvantage Software," commented Tareq Abu-Nadi, BioTox Sciences, Business Development/Study Director.  "eStudy will complement and streamline the study processes conducted at BTS by increasing productivity and speed of reporting while maintaining 21 CFR parts 58 and 11 compliance."

"eStudy's flexibility ensures that BTS Study Directors would be able to use eStudy on various projects and multiple species.  Whether a typical 28 day toxicity study in rats or dogs, or a long term surgery study in NHPs, eStudy will be used to manage the study, capture the data and allow for on-demand reporting of results upon Sponsor request.  This significant investment gives us the ability to produce complete study books in mere hours, and help Sponsors make key decisions on development of compounds and initiate more projects," concluded Abu-Nadi.

eStudy is a 100% web-based study management platform that iAdvantage Software hosts for BTS at Cegidem/Dendrite's world-class network operating center in Chesapeake, VA.  "eStudy will continually grow with BioTox Sciences, easily adapt to new study-types, marry to BTS' operational work-flow and interface with 3rd party instruments and tools," stated Diana Michelotti, Director of Marketing and Sales for iAdvantage.  "eStudy implemented for BTS, provides BTS with a custom fit solution without the start-from-scratch price."

About iAdvantage SoftwareiAdvantage is dedicated to empowering scientists and management in the pharmaceutical and biotechnology arenas with efficient, web-based electronic study management and reporting tools that automate cumbersome tasks and optimize time to results thereby improving productivity, real-time business intelligence and time to market.

iAdvantage products include eStudy, a truly web-based enterprise solution for study design, eNotebook design, collection of data from multiple sources, multiple users and multiple locations, integration of data in real-time to a secure storage device, maintaining data integrity (complying with 21 CFR Parts 58 and 11) with the flexibility of on-demand access, data analysis and reporting that is user-defined and user-controlled.  iAdvantage places control in the hands of the scientist and not at the mercy of rigid study management systems.

iAdvantage is headquartered in Cary, North Carolina, near the life science and biotech hub of Research Triangle Park.  More than 140 life science companies in North America and Europe use iAdvantage products in their research and development.  Please visit www.iadvantagesoftware.com for more information.

About BioTox SciencesBioTox Sciences, San Diego, CA, is a leading Contract Research Organization (CRO) offering comprehensive services for nonclinical and preclinical studies operates a state of the art 20,000 sqf AAALAC accredited vivarium.  BioTox Sciences services encompass toxicology, pharmacology, metabolism, disease models, surgery models, behavior and safety testing, PK/PD and other customized testing in support of nonclinical drug development for pharmaceutical, biotechnology and medical device companies.  Visit www.biotoxsciences.com/ for more information.Inquires:Diana MichelottiDirector of Marketing and SalesiAdvantage Software, Inc. - 919-469-3888 ext. 121dmichelotti@iadvantagesoftware.comTareq Abu-NadiBusiness Development/Study DirectorBioTox Sciences - 858-605-5882 ext. 302tabunadi@biotoxsciences.com
'/>"/>

SOURCE iAdvantage Software, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
3. RBC Life Sciences Reports Sales and Earnings Growth in 2010
4. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
5. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
6. Novavax Licenses Recombinant VLP Influenza Vaccine to LG Life Sciences for South Korea and Other Countries
7. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
8. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
9. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
10. Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
11. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016  Sequent Medical, Inc. gab heute bekannt, ... eine Studie zur Sicherheit und Wirksamkeit des WEB™-Systems ... Behandlung von rupturierten intrakraniellen Aneurysmen begonnen hat. Prof. ... an der Universitätsklinik Bicètre in Paris ... den ersten Patienten aufgenommen. Im Rahmen ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company (NYSE: ... decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not ... UK, France , Italy ... dilute the product only with dextrose solution.  ... the UK Court of Appeal held that Lilly,s patent would ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... the life cycle of pharmaceutical products, garnering increased attention from all stakeholders in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut water beverages ... GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature ... event. The invitation-only gifting suite, held this year at the W Hollywood Hotel, has ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a ... offer real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a locally owned insurance firm ... that will raise funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd ... school is in a low-income area and has more than 60 2nd and 3rd ...
Breaking Medicine News(10 mins):